EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Observed Immune Response Following Histotripsy in Metastatic Hepatocellular Carcinoma

Christopher Staley, Tahani Dakkak, Shane S Robinson iD, Nelson A Royall

Case Reports in Oncological Medicine · 2026-01 · 2026 (1)

DOI: 10.1155/crom/4245816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Oncological Medicine, online erschienen am 17.04.2026. Verfasst von Christopher Staley und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Department of Graduate Medical Education, Northeast Georgia Medical Center, Gainesville, Georgia, USA. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Histotripsy is a novel, noninvasive, nonthermal tumor ablation therapy that uses focused ultrasound to mechanically disrupt tissue. Emerging evidence suggests that histotripsy may stimulate antitumor immune responses. To our knowledge, this is one of the first reported cases of histotripsy used in conjunction with systemic immunotherapy in a patient with hepatocellular carcinoma (HCC), resulting in an observed systemic immune response in nontarget lesions. Case Presentation A 63‐year‐old male with noncirrhotic, nonviral multifocal metastatic HCC was treated with combination systemic immunotherapy (atezolizumab plus bevacizumab), followed by targeted histotripsy ablation of hepatic Segment II lesions. Given the presence of extrahepatic metastatic disease, liver transplantation was not a viable option. Posthistotripsy imaging demonstrated a partial response in the targeted lesion but partial responses in multiple nontarget lesions. This radiographic response occurred after discontinuation of systemic therapy due to toxicity. The patient maintained excellent functional status and continues to undergo histotripsy treatment.

Conclusion

This case highlights the potential for histotripsy to elicit an abscopal‐like immune response in metastatic HCC when combined with immunotherapy. Histotripsy may serve as a valuable adjunct to systemic therapy, particularly in patients unable to tolerate prolonged immunotherapy. Further studies are warranted to explore this potential synergy in controlled clinical trials.

Schlagwörter

Stichwörter der Autor:innen

hepatocellular carcinomahistotripsyimmunotherapyliver cancerobserved immune response

Autor:innen und Institutionen

  • Department of General Surgery, Department of Graduate Medical Education, Northeast Georgia Medical Center, Gainesville, Georgia, USA.
  • Division of Research, Department of Graduate Medical Education, Northeast Georgia Medical Center, Gainesville, Georgia, USA.
  • General Surgery Residency Program, Department of Graduate Medical Education, Hepato-Pancreato-Biliary Surgery, Northeast Georgia Medical Center, Gainesville, Georgia, USA.

ORCID-Profile: Shane S Robinson

Zitieren

APA

Staley, C., Dakkak, T., Robinson, S. S., & Royall, N. A. (2026). Observed Immune Response Following Histotripsy in Metastatic Hepatocellular Carcinoma. Case Reports in Oncological Medicine, 2026(1). https://doi.org/10.1155/crom/4245816

Vancouver

Staley C, Dakkak T, Robinson SS, Royall NA. Observed Immune Response Following Histotripsy in Metastatic Hepatocellular Carcinoma. Case Reports in Oncological Medicine. 2026;2026(1). doi:10.1155/crom/4245816

BibTeX
@article{Staley2026,
  author = {Staley, Christopher and Dakkak, Tahani and Robinson, Shane S and Royall, Nelson A},
  title = {Observed Immune Response Following Histotripsy in Metastatic Hepatocellular Carcinoma},
  journal = {Case Reports in Oncological Medicine},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crom/4245816}
}
Kostenlos starten →